Given the importance of identifying new therapies for BED and the promising outcomes associated with GLP-1 receptor agonists, this article systematically reviews the effects of these drugs on BED, with a specific focus on their impact on anthropometric variables. The gene discussed is GLP1R; the disease is X-linked cone dysfunction syndrome with myopia.